SCHEDULE: Frazier Funds Update KalVista Ownership Stakes
Schedule 13D Amendment
Frazier Life Sciences funds filed an amended Schedule 13D for KalVista Pharmaceuticals, Inc., clarifying beneficial ownership percentages and attribution.
Summary
- Frazier Life Sciences Public Fund, L.P., along with its general partners FHMLSP, L.P. and FHMLSP, L.L.C., collectively beneficially own 2,400,276 shares of KalVista Pharmaceuticals, Inc. Common Stock, representing 4.8% of the class.
- Frazier Life Sciences Public Overage Fund, L.P., FHMLSP Overage, L.P., and FHMLSP Overage, L.L.C. collectively beneficially own 946,074 shares, representing 1.9% of the class.
- Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., James N. Topper, and Patrick J. Heron collectively beneficially own 1,156,869 shares, representing 2.3% of the class.
- Frazier Life Sciences XI, L.P., FHMLS XI, L.P., and FHMLS XI, L.L.C. collectively beneficially own 384,648 shares, representing 0.8% of the class.
- The amendment clarifies that, with the exception of James N. Topper and Patrick J. Heron regarding FLS X Shares, individual members of the investment committees are not attributed beneficial ownership of the securities directly held by the funds.
- The percentage of class is calculated based on 49,953,739 shares of KalVista's Common Stock outstanding as of June 25, 2025, as reported in the Issuer's Annual Report on Form 10-K filed on July 10, 2025.
Sentiment
Score: 5
Explanation: The filing is a routine amendment to a Schedule 13D, primarily clarifying beneficial ownership attribution rather than indicating a change in investment intent or company performance. It is neutral in sentiment.
Future Outlook
NA
Industry Context
This filing reflects the ongoing investment activities of specialized life sciences funds, Frazier Life Sciences, in a publicly traded biotechnology company, KalVista Pharmaceuticals. Such filings are routine for significant institutional investors to update their ownership stakes and clarify reporting structures within the dynamic biotech and pharmaceutical investment landscape.
Stakeholder Impact
- Shareholders: Provides updated information on significant beneficial ownership stakes and clarifies the attribution of these shares among various Frazier Life Sciences entities and their principals.
Key Dates
| Date | Description |
|---|---|
| 2021-12-30 | Original Schedule 13D filing date. |
| 2022-01-26 | Date of first amendment to Schedule 13D. |
| 2022-12-30 | Date of second amendment to Schedule 13D. |
| 2023-12-14 | Date of third amendment to Schedule 13D. |
| 2024-02-22 | Date of fourth amendment to Schedule 13D. |
| 2024-11-07 | Date of fifth amendment to Schedule 13D. |
| 2025-06-25 | Date as of which 49,953,739 shares of KalVista's Common Stock were outstanding, as reported in the Issuer's 10-K. |
| 2025-07-10 | Date KalVista's Annual Report on Form 10-K was filed with the SEC. |
| 2025-08-18 | Date of event requiring the filing of this Amendment No. 6 to Schedule 13D. |
| 2025-08-20 | Signature date of this Amendment No. 6 to Schedule 13D. |
Keywords
KalVista Pharmaceuticals, Frazier Life Sciences, Schedule 13D, Beneficial Ownership, Biotechnology, Pharmaceuticals, Investment Fund, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.